Amy Sprague, MD
Nephrology · Georgetown, SCNPI 1629030598
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,130 of the $7,884 with a category attached, or 90.4%. Outset Medical Inc accounts for 90.4% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $7,130 and has fallen 99.1% since, to $64 in 2025.
Across 12 payments — averaging $657.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Outset Medical Inc$7K
- Paratek Pharmaceuticals, Inc.$125
- Portola Pharmaceuticals, LLC$122
- Acelrx Pharmaceuticals, Inc.$101
- Astellas Pharma US Inc$97
- Tetraphase Pharmaceuticals, Inc.$90
- plus $219 from 5 others
Across 167 payments — averaging $9167.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$722K
- Eli Lilly$572K
- Astrazeneca UK Limited$70K
- Pfizer$50K
- AbbVie$25K
- AstraZeneca$24K
- plus $67K from 6 others
What the payments were for
- Speaking & faculty fees$7,13090%
- Food & beverage$75410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Outset Medical Inc | 1 | $7,130 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Portola Pharmaceuticals, LLC | 1 | $122 |
| Acelrx Pharmaceuticals, Inc. | 1 | $101 |
| Astellas Pharma US Inc | 1 | $97 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $90 |
| Nxstage Medical, Inc. | 1 | $66 |
| Baxter Healthcare | 1 | $57 |
| Sanofi | 1 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Stryker | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,884 in reported general payments places this provider in the 80th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 14 | $9,325 |
| Pantoprazole Sodium | 12 | $198 |
| Levothyroxine Sodium | 17 | $195 |
| Methylprednisolone | 14 | $110 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Georgetown
- Jessica ColemanBeaufort$930K
- Moustafa MoustafaOrangeburg$616K
- Harold SzerlipCharleston$229K
- Barry GorlitskyGreenville$195K
- Blake ShustermanGreenville$66K
- Martin WebbBeaufort$66K
- Mohammed AlzubaidiSumter$54K
- Joshua LipschutzCharleston$44K
- Renee EllisColumbia$40K
- Charles BunkeCharleston$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.